Xeljanz and Fluid retention - a phase IV clinical study of FDA data

Summary:

Fluid retention is reported as a side effect among people who take Xeljanz (tofacitinib citrate), especially for people who are female, 60+ old, have been taking the drug for 1 - 6 months also take Actemra, and have Pain.

The phase IV clinical study analyzes which people have Fluid retention when taking Xeljanz. It is created by eHealthMe based on reports of 238,928 people who have side effects when taking Xeljanz from the FDA, and is updated regularly.

What is Xeljanz?

Xeljanz has active ingredients of tofacitinib citrate. It is often used in rheumatoid arthritis. eHealthMe is studying from 239,081 Xeljanz users. Check the latest studies of Xeljanz.

What is Fluid retention?

Fluid retention (an abnormal accumulation of fluid in the blood) is found to be associated with 1,700 drugs and 2,447 conditions by eHealthMe. Check the latest studies of Fluid retention.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 20, 2026

238,928 people reported to have side effects when taking Xeljanz.
Among them, 776 people (0.32%) have Fluid retention.

Among these 776 people:

* Approximation only. Some reports may have incomplete information.

Do you take Xeljanz and have Fluid retention?

- Check whether Fluid retention is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Xeljanz:

Xeljanz (239,081 reports)

Fluid retention treatments and more:

Fluid retention (79,660 reports)

How severe was Fluid retention and when was it recovered:

Fluid retention in Xeljanz

Expand to all the drugs that have ingredients of tofacitinib citrate:

Fluid retention and drugs with ingredients of tofacitinib citrate (776 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Xeljanz:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Fluid retention:

Fluid retention (1,700 drugs)

Browse all the conditions that are associated with Fluid retention:

Fluid retention (2,447 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on tofacitinib citrate (the active ingredients of Xeljanz) and Xeljanz (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.